Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 9 Issue 2, February 2010

Volume 9 Issue 2

Subscribe

In This Issue

Top of page ⤴

Comment

Top of page ⤴

News and Analysis

  • In a year in which regulators and drug companies gained familiarity with risk management strategies, the number of new drug approvals was similar to that in 2008.

    • Bethan Hughes
    News and Analysis
Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

News and Analysis

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

  • The Chairman and former Chief Executive Officer of Novartis discusses the company's approach to R&D.

    • Bethan Hughes
    An Audience With
Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Michael J. Keating
    • Argyris Dritselis
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

  • Long-term therapeutic options for the treatment of obesity are limited. In his Perspective, Cao discusses the functions of the vasculature within adipose tissue — particularly its role in tissue growth and development, and the potential of targeting adipose tissue angiogenesis as a novel anti-obesity therapy.

    • Yihai Cao
    Opinion
Top of page ⤴

Review Article

  • The growing prevalence of multidrug-resistant bacterial strains, together with the decline in the discovery of novel antibacterial agents, has made the effective treatment of many bacterial infections increasingly difficult. Here, Rasko and Sperandio review bacterial virulence mechanisms and discuss the potential of emerging anti-virulence therapeutic strategies.

    • David A. Rasko
    • Vanessa Sperandio
    Review Article

  • Idiopathic pulmonary fibrosis (IPF) is a life-threatening chronic lung disease, for which no specific therapies have been approved. In this article, du Bois discusses the current understanding of the pathophysiology of IPF, the potential of agents under development and possible future therapeutic strategies.

    • R. M. du Bois
    Review Article

  • In this Review the authors discuss the current understanding of the role of the chemokine system in cardiovascular disease and highlight potential therapeutic approaches for atherosclerosis, such as modified chemokine ligands, small-molecule antagonists and disruption of heterophilic chemokine interactions.

    • Rory R. Koenen
    • Christian Weber
    Review Article

  • Although currently available antiplatelet therapies have proved effective in preventing cardiovascular events and reducing mortality, they are not without limitations. Here, Michelson discusses recent advances in understanding of the molecular basis of the role of platelets in cardiovascular disease and the resultant emerging novel therapies and strategies.

    • Alan D. Michelson
    Review Article
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Advanced search

Quick links